Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA Testing

被引:25
|
作者
Mannis, Gabriel N. [1 ]
Fehniger, Julia E. [2 ]
Creasman, Jennifer S. [3 ,4 ]
Jacoby, Vanessa L. [3 ]
Beattie, Mary S. [2 ,4 ]
机构
[1] Univ Calif San Francisco, Div Hematol Oncol, Dept Internal Med, San Francisco, CA 94117 USA
[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Canc Risk Program, San Francisco, CA 94117 USA
[3] Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94117 USA
[4] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94117 USA
关键词
BREAST-CANCER; CLINICAL CHARACTERISTICS; MUTATION CARRIERS; REDUCTION; TIME; METAANALYSIS; ASSOCIATION; PREDICTORS; ULTRASOUND; EFFICACY;
D O I
10.1001/2013.jamainternmed.962
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For women at potentially increased risk for ovarian cancer, data regarding screening and risk reduction are limited. Previous studies have reported on the behaviors of BRCA mutation carriers, but less is known about the behaviors of non-BRCA carriers. We surveyed a large cohort of women after BRCA testing to identify the prevalence and posttest predictors of risk-reducing and screening interventions. Methods: A median of 3.7 years after BRCA testing, 1447 women who received genetic counseling and BRCA testing at 2 hospital sites were surveyed, with a 77.6% response rate. We analyzed data from 1077 survey respondents. We performed univariate and multivariate logistic regression analyses to identify predictors of risk-reducing salpingo-oophorectomy (RRSO), screening transvaginal ultrasonography (TVUS), and screening serum cancer antigen 125 (CA-125). Results: Among the respondents, 201 women (18.7%) received positive test results for a deleterious mutation, 103 women (9.6%) received true-negative results, and 773 women (71.8%) received uninformative results. Over-all, 19.1% of eligible women underwent RRSO and 39.6% used screening procedures. A positive BRCA result predicted RRSO (odds ratio [OR], 28.1; 95% CI, 16.2-48.6), TVUS (9.5 [4.3-21.0]), and serum CA-125 (13.0 [5.5-29.0]). Similarly, a true-negative BRCA result reduced the OR for RRSO (0.1 [0.0-0.6]), TVUS (0.2 [0.1-0.5]), and serum CA-125 (0.3 [0.1-0.7]). Of the 71.8% of women who received uninformative results after BRCA testing, 12.3% subsequently underwent RRSO, 33.8% reported ever having undergone screening serum CA-125 since BRCA testing, and 37.3% reported ever having undergone screening TVUS since BRCA testing. Conclusions: Results of BRCA testing strongly predict RRSO and ovarian cancer screening. Use of RRSO and ovarian screening was reported in a sizable percentage of non-BRCA carriers despite insufficient data to determine the effectiveness of these interventions. JAMA Intern Med. 2013; 173(2):96-103. Published online December 17, 2012. doi:10.1001/2013.jamainternmed.962
引用
收藏
页码:96 / 103
页数:8
相关论文
共 50 条
  • [21] Impact of lower co-payments on risk-reducing salpingo-oophorectomy and BRCA testing in Japan
    Konnai, Katsuyuki
    Fujiwara, Hiroyuki
    Kitagawa, Masakazu
    Wakabayashi, Reina
    Yumori, Asuna
    Notomi, Tsuguto
    Onose, Ryo
    Kato, Hisamori
    Narimatsu, Hiroto
    ARCHIVES OF PUBLIC HEALTH, 2023, 81 (01)
  • [22] Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy
    Rowen, Tami S.
    SEXUAL MEDICINE, 2016, 4 (01): : E3 - E4
  • [23] Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy
    Tucker, Paige E.
    Bulsara, Max K.
    Salfinger, Stuart G.
    Tan, Jason Jit-Sun
    Green, Helena
    Cohen, Paul A.
    GYNECOLOGIC ONCOLOGY, 2016, 140 (01) : 95 - 100
  • [24] Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer
    Hidetaka Nomura
    Ai Ikki
    Atsushi Fusegi
    Makiko Omi
    Yoichi Aoki
    Sachiho Netsu
    Terumi Tanigawa
    Maki Matoda
    Sanshiro Okamoto
    Kohei Omatsu
    Takeshi Nakajima
    Arisa Ueki
    Akiko Tonooka
    Hiroyuki Kanao
    International Journal of Clinical Oncology, 2021, 26 : 2331 - 2337
  • [25] Impact of lower co-payments on risk-reducing salpingo-oophorectomy and BRCA testing in Japan
    Katsuyuki Konnai
    Hiroyuki Fujiwara
    Masakazu Kitagawa
    Reina Wakabayashi
    Asuna Yumori
    Tsuguto Notomi
    Ryo Onose
    Hisamori Kato
    Hiroto Narimatsu
    Archives of Public Health, 81
  • [26] Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series
    Ricciardi, Enzo
    Tomao, Federica
    Aletti, Giovanni
    Bazzurini, Luca
    Bocciolone, Luca
    Boveri, Sara
    Landoni, Fabio
    Lapresa, Maria Teresa
    Maruccio, Matteo
    Parma, Gabriella
    Peccatori, Fedro
    Petrella, Maria Cristina
    Zanagnolo, Vanna
    Colombo, Nicoletta
    Maggioni, Angelo
    ANTICANCER RESEARCH, 2017, 37 (09) : 5241 - 5248
  • [27] Fatigue and Quality of Life After Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Hereditary Breast-Ovarian Cancer
    Michelsen, Trond M.
    Dorum, Anne
    Trope, Claes G.
    Fossa, Sophie D.
    Dahl, Alv A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2009, 19 (06) : 1029 - 1036
  • [28] Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer
    Nomura, Hidetaka
    Ikki, Ai
    Fusegi, Atsushi
    Omi, Makiko
    Aoki, Yoichi
    Netsu, Sachiho
    Tanigawa, Terumi
    Matoda, Maki
    Okamoto, Sanshiro
    Omatsu, Kohei
    Nakajima, Takeshi
    Ueki, Arisa
    Tonooka, Akiko
    Kanao, Hiroyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (12) : 2331 - 2337
  • [29] Risk-Reducing Salpingo-Oophorectomy for BRCA Carriers: Is There a Benefit to Combined Breast Surgery?
    Liu, Cici
    Monier, Elizabeth
    Brady, Rachel
    Kehoe, Siobhan
    OBSTETRICS AND GYNECOLOGY, 2016, 127 : 138S - 138S
  • [30] Considerations for the Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy
    Zhang, Jindong
    Liu, Maoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32)